Strands from the Web
|

Generic drugmakers warn that rising costs of FDA manufacturing inspections are causing shortages of critical generic drugs.

Larry Kotlikoff explains why corporate income taxes are regressive.

President Obama's proposal to slash market exclusivity for biotech medicines - and industry's angry response.

Hypermutations enable deadly prostate cancers to resist treatment. (More evidence that "genomic chaos" underpins cancer's lethal power.)

CLASS program is closed, erasing $70 billion in deficit reduction - that may never have existed anyway.

House Budget Chairman Paul Ryan delivers his vision for health care reform.

Surprise, surprise: employer health insurance premiums are up. (You can find the full study here.) 

Fight intensifies over proposed Medicare drug rebates.  (For more detail on what's at stake, see this recent report from the American Action Forum.)

FDA scrutinizes potentially higher risk of blood clots for certain birth control pills. 

The new issue of National Affairs is out.

Related Entries:


keep in touch     Follow Us on Twitter  Facebook  Facebook


Our Research

Rhetoric and Reality—The Obamacare Evaluation Project: Cost
by Paul Howard, Yevgeniy Feyman, March 2013


Warning: mysql_connect(): Unknown MySQL server host 'tmiweb52.vwh.net' (2) in /home/medicalp/public_html/incs/reports_home.php on line 17
Unknown MySQL server host 'tmiweb52.vwh.net' (2)
Archives

Blogroll

American Council on Science and Health
in the Pipeline
Drugwonks
Pharmalot
Reason – Peter Suderman
WSJ Health Blog
The Hill’s Healthwatch
Forbes ScienceBiz
The Apothecary
EyeOnFDA
KevinMD
Marginal Revolution
Megan McArdle
LifeSci VC
Critical Condition
EconLog
In Vivo Blog
PharmaGossip
Pharma Strategy Blog
Drug Discovery Opinion